Search results for "Cure rate"

showing 2 items of 2 documents

FISSIT (Fistula Surgery in Italy) study: A retrospective survey on the surgical management of anal fistulas in Italy over the last 15 years

2021

Background: Surgical treatment of anal fistulas is still a challenge. The aims of this study were to evaluate the adoption and healing rates for the different surgical techniques used in Italy over the past 15 years. Methods: This was a multicenter retrospective observational study of patients affected by simple and complex anal fistulas of cryptoglandular origin who were surgically treated in the period 2003–2017. Surgical techniques were grouped as sphincter-cutting or sphincter-sparing and as technology-assisted or techno-free. All patients included in the study were followed for at least 12 months. Results: A total of 9,536 patients (5,520 simple; 4,016 complex fistulas) entered the stu…

Anal fistulaMalemedicine.medical_specialtyCure rateFistulaSettore MED/18 - CHIRURGIA GENERALEAnal CanalAnal Canal; Fecal Incontinence; Female; Follow-Up Studies; Humans; Incidence; Italy; Male; Middle Aged; Population Surveillance; Postoperative Complications; Rectal Fistula; Retrospective Studies; ForecastingFistulotomyFollow-Up StudiePostoperative ComplicationsRetrospective surveyRetrospective StudiemedicineHumansRectal FistulaAnal fistulaSurgical treatmentRetrospective Studiesanorectal fistulabusiness.industryIncidenceRetrospective cohort studyMiddle Agedmedicine.diseaseSurgerySettore MED/18ItalyPopulation SurveillanceSurgeryFemalePostoperative ComplicationbusinessFecal IncontinenceHumanFollow-Up StudiesForecasting
researchProduct

Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis.

2004

1. A study performed > 10 years ago and case reports published recently suggest that triclabendazole is effective for the treatment of patients with fascioliasis. 2. To confirm the efficacy of a human formulation of triclabendazole, we enrolled 165 patients into the present study and divided the subjects into two groups: (i) those who had fascioliasis, as evidenced by the presence of ova in their stools; and (ii) patients with clinical and laboratory data suggesting fascioliasis. 3. Patients were randomly allocated to receive 10 mg/kg, p.o., triclabendazole for 1, 2 or 3 days (single-, double- and triple-dose groups, respectively). Medical history and physical and laboratory examinations we…

Toxic hepatitisAdultMalemedicine.medical_specialtyCure rateFascioliasisAdolescentPhysiologyChemistry PharmaceuticalGastroenterologylaw.inventionFecesRandomized controlled triallawOral administrationPhysiology (medical)Internal medicineMedicineHumansMedical historyIn patientChildTriclabendazoleAgedPharmacologyAnthelminticsDose-Response Relationship Drugbusiness.industryMiddle AgedSurgeryTriclabendazoleTreatment OutcomeHuman fascioliasisImmunoglobulin GBenzimidazolesFemalemedicine.symptombusinessmedicine.drugClinical and experimental pharmacologyphysiology
researchProduct